Protagonist Therapeutics (PTGX) Share-based Compensation (2015 - 2026)

Protagonist Therapeutics has reported Share-based Compensation for 12 years, with the latest figure at $14.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 5.19% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 6.66% YoY) and the FY2025 annual result came in at $78.0 million, up 37.08% from the prior year.
• Share-based Compensation improved to $14.5 million in Q1 2026 per PTGX's latest filing, from -$11.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.5 million in Q1 2026 and troughed at -$18.0 million in Q4 2024.
• A 5-year average of $1.5 million and a median of $2.6 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 3340.14% in 2023, then surged 1080.31% in 2024.
• Over 5 years, Share-based Compensation stood at $553000.0 in 2022, then plunged by 3340.14% to -$17.9 million in 2023, then fell by 0.18% to -$18.0 million in 2024, then soared by 33.54% to -$11.9 million in 2025, then soared by 221.7% to $14.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $14.5 million, -$11.9 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.